Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | F3 | P13726 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23967339 | 1.00 | MAPT (0.59) | MAPTABCC4LMNAALDH1A1FAAH | |
| SCHEMBL18571970 | 0.91 | MAPT (0.49) | MAPTABCC4LMNAALDH1A1FAAH | |
| SCHEMBL31591585 | 0.88 | LMNA (0.54) | MAPTLMNAALDH1A1FAAH | |
| SCHEMBL20340354 | 0.88 | LMNA (0.53) | MAPTABCC4LMNAALDH1A1FAAH | |
| SCHEMBL15540840 | 0.88 | LMNA (0.59) | MAPTABCC4LMNAALDH1A1FAAH | |
| SCHEMBL7867823 | 0.85 | ALDH1A1 (0.47) | MAPTABCC4LMNAALDH1A1FAAH | |
| SCHEMBL31438724 | 0.85 | MAPT (0.62) | MAPTABCC4LMNAALDH1A1USP2 | |
| SCHEMBL31438745 | 0.85 | MAPT (0.62) | MAPTABCC4LMNAALDH1A1USP2 | |
| SCHEMBL31438723 | 0.85 | MAPT (0.62) | MAPTABCC4LMNAALDH1A1USP2 | |
| SCHEMBL31438734 | 0.85 | MAPT (0.62) | MAPTABCC4LMNAALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011556-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170057905-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYN HOLDINGS, LLC | 2017-03-02 | — | — | US | disclosed |
| US-20160244397-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND BIOBASED COMPOUNDS THAT INCLUDE ETHYLENEOLYSIS | BIOSYN HOLDINGS, LLC | 2016-08-25 | — | — | US | disclosed |
| US-20160244397-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND BIOBASED COMPOUNDS THAT INCLUDE ETHYLENEOLYSIS | BIOSYN HOLDINGS, LLC | 2016-08-25 | — | — | US | disclosed |
| WO-2016134138-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND BIOBASED COMPOUNDS THAT INCLUDE ETHYLENEOLYSIS | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| US-9403752-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403752-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160137946-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYN HOLDINGS, LLC | 2016-05-19 | — | — | US | disclosed |
| US-20160137946-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYN HOLDINGS, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9199911-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199911-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140012023-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140012023-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2014-01-09 | — | — | US | disclosed |
| US-8580985-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580985-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2013095945-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYNTHETIC TECHNOLOGIES, LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158277-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYN HOLDINGS, LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158277-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | BIOSYN HOLDINGS, LLC | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012023-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | SQLE, ALOX12, ALOX15 | MAPT 2801/4885ABCC4 4321/4885LMNA 318/4885 |
| US-20130158277-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | SQLE, ALOX12, ALOX15 | MAPT 2801/4885ABCC4 4321/4885LMNA 318/4885 |
| US-20160244397-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND BIOBASED COMPOUNDS THAT INCLUDE ETHYLENEOLYSIS | ELOVL1, FASN, ELOVL5 | MAPT 3947/4885ABCC4 4794/4885LMNA 720/4885 |
| US-20170057905-A1 | PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS | SQLE, ALOX12, ALOX15 | MAPT 2801/4885ABCC4 4321/4885LMNA 318/4885 |
| US-10011556-B2 | Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis | SQLE, ALOX12, ALOX15 | MAPT 2801/4885ABCC4 4321/4885LMNA 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.